胃食管癌扩大淋巴结清扫术的西方大样本结局
该研究分析了520例胃食管癌根治性切除患者,比较局限(D0/D1)与扩大(D1+/D2)淋巴结清扫的围手术期风险与生存。扩大清扫组淋巴结检出数更多,但主要并发症和手术死亡率无差异。单因素分析显示扩大清扫与总生存改善相关,但校正手术时期后生存获益消失。
要点
- 扩大淋巴结清扫(D1+/D2)在高容量西方中心可安全施行。
- 扩大清扫显著提高淋巴结检出数,确保准确病理分期。
- 校正手术时期后,扩大清扫的总生存获益消失。
核心结论
- 胃食管癌扩大(D1+/D2)淋巴结清扫可安全施行,显著提高淋巴结检出数并确保准确病理分期。
- 单因素分析显示扩大清扫与总生存改善相关,但校正手术时期后该生存获益消失。
研究设计与样本
- 单中心回顾性分析1995至2017年520例接受潜在根治性切除的胃食管癌患者。
- 362例(70%)行D0/D1淋巴结清扫,158例(30%)行D1+/D2淋巴结清扫。
- 中位随访3.1年,分析围手术期并发症、死亡率、淋巴结检出数及总生存。
主要发现
- D1+/D2组中位淋巴结检出数为27枚,≥16枚者占89%;D0/D1组分别为16枚和53%。
- D0/D1组与D1+/D2组主要并发症率分别为16.6%与14.6%,手术死亡率分别为2.8%与0.6%,均无差异。
- 单因素分析中D1+/D2组总生存显著改善(风险比0.74;p=0.035),校正手术时期后生存获益消失。
临床怎么用
- 在高容量中心,胃食管癌根治术可考虑行D1+/D2淋巴结清扫以获取准确分期。
- 扩大清扫的生存获益需结合手术时期等因素谨慎解读。
局限性
- 单中心回顾性设计,可能存在选择偏倚。
- D1+/D2组更多为远端肿瘤、远端/次全/全胃切除及较近期手术,混杂因素影响结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The extent of lymph node dissection for patients with gastroesophageal carcinoma remains controversial. We sought to examine the perioperative risk and survival outcomes in a large Western series of patients undergoing limited (D0/D1) vs extended (D1+/D2) lymphadenectomy (LAD) for gastroesophageal carcinoma. STUDY DESIGN: Clinicopathologic and treatment factors for 520 patients with gastroesophageal carcinoma undergoing potentially curative resection at a single institution from 1995 to 2017 were analyzed for their impact on perioperative morbidity and mortality, lymph node yield, and overall survival. RESULTS: A total of 362 (70%) patients underwent D0/D1 LAD and 158 (30%) underwent D1+/D2 LAD. Median follow-up was 3.1 years. Patients undergoing D1+/D2 LAD were more likely to have distal tumors, to undergo distal/subtotal/total gastrectomy, and to undergo operation at a more contemporary time than patients undergoing D0/D1 LAD. The median number of lymph nodes examined and the percentage of patients with 16 or more lymph nodes examined was 16 and 53%, respectively, in the D0/D1 group vs 27 and 89%, respectively, in the D1+/D2 group. There were no differences in the rates of major complications (16.6% vs 14.6%) or operative mortality (2.8% vs 0.6%) between the D0/D1 and D1+/D2 groups, respectively. Patients undergoing D1+/D2 LAD had significantly improved overall survival (hazard ratio 0.74; p = 0.035) compared with those undergoing D0/D1 LAD on univariate analysis, but this survival benefit disappeared when controlling for the time period of operation. CONCLUSIONS: Gastrectomy with extended (D1+/D2) LAD can be performed safely at a high-volume Western center, and it improves nodal yield significantly and ensures accurate pathologic staging.
引用
- Li SS, Costantino CL, Rattner DW, et al. Outcomes of Extended Lymphadenectomy for Gastroesophageal Carcinoma: A Large Western Series. J Am Coll Surg. 2019. PMID: 30825638. doi:10.1016/j.jamcollsurg.2019.02.044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。